Fulfilment of the condition for the Issuer’s shares to be admitted to trading
30.03.2026
See also
Synektik plans to devide. It is spinning off the cardiotracer research project into a new company which will also be listed on the WSE
- Corporate news
- Investor relations
Synektik one step closer to planned division
- Corporate news
- Investor relations
KNF has approved the Syn2bio prospectus. The debut on the WSE is planned for April
- Corporate news
- Investor relations